Total revenues of $167.1 million Net product sales of $132.4 million for EXPAREL, $25.8 million for ZILRETTA, and $5.0 million for iovera° Net income of $9.0 million, or $0.19 per share (basic and ...
In 2021, it was estimated that about 23% of adults living in Las Vegas, NV had arthritis. Osteoarthritis (OA), the most common form of arthritis, affects millions of people worldwide. OA symptoms can ...
19d
Pacira Announces Agreement with LG Chem to Make EXPAREL® Available in Select Asian-Pacific Markets
LG Chem is an established leader in pain management with a proven track record of delivering orthopedic pain solutions to patients across Asia,” said Frank D. Lee, chief executive officer of Pacira ...
See “Non-GAAP Financial Information” below. “We entered 2025 sharply focused on our 5x30 strategy and our transition into an innovative biopharmaceutical organization,” said Frank D. Lee, chief ...
Pacira BioSciences PCRX announced results from a pilot study evaluating the unique therapeutic approach of its iovera system compared to radiofrequency ablation (RFA) for chronic low back pain (CLBP).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results